US biotech BioAtla has signed a license and option agreement with Pfizer to advance the development and commercialisation of a new class of antibody therapeutics.
News
Roche buys into SQZ engineering tech in $500m deal
Roche and SQZ Biotech are working together on a cell therapy platform that would empower a patient’s own immune cells to fight a broad range of cancers.
Sandoz files Enbrel biosimilar in the EU
European regulators have accepted Sandoz’ marketing application for a biosimilar of Pfizer’s $9-billion-a-year anti-inflammatory Enbrel, the world’s fifth biggest selling drug.
FDA clears Alexion’s enzyme replacement therapy Kanuma
US regulators have issued a green light for Alexion’s long-term enzyme replacement therapy Kanuma, giving patients with the ultra rare genetic disorder lysosomal acid lipase deficiency access to a targeted treatment for the first time.
Five medicines cleared for use by NHS Scotland
Five medicines have been accepted by cost regulators for routine use on the NHS in Scotland, offering patients access to new options for lung cancer, multiple myeloma, opioid-induced constipation and the chronic skin condition rosacea.
Free wi-fi across NHS among new digital proposals
Baroness Martha Lane Fox has laid out her digital proposals for the NHS, including ensuring that every building in the health service has free wi-fi.
Amgen files Humira biosimilar in EU, signs Merck deal
Amgen has filed the first biosimilar version of AbbVie’s anti-inflammatory super-blockbuster Humira in the European Union, in the hope of offering a cheaper alternative to the drug and thus potentially improving access to it.
AZ, Voluntis test companion app for ovarian cancer treatment
AstraZeneca has unveiled plans to test a new digital support service for women undergoing treatment for platinum-sensitive high-grade ovarian cancer in clinical trials testing a combination of cediranib plus Lynparza.
Charity calls on NICE to reverse rejection of Amgen’s PCSK9 inhibitor
Cholesterol charity HEART UK is calling on NICE to reverse its rejection of Amgen’s cholesterol-busting drug Repatha for use on the National Health Service in England and Wales, slamming the move for leaving high-risk patients in danger of suffering heart attack or stroke.
GPs prescribing fewer antibiotics score less on patient satisfaction
Researchers from King’s College London have found that GPs dishing out fewer antibiotics are rating lower on patient satisfaction, indicating that a significant shift in public perception is still needed to help curb their use and pull back the rise of antimicrobial resistance.
Lilly, Merck drop late-stage diabetes, cancer drugs
Pharmaceutical giants Lilly and Merck KGaA have taken a hit to their late-stage research and development pipelines with the failure of their respective experimental drugs for diabetes and cancer.
Promising results for Novartis’ blood cancer CART therapy
Novartis’ experimental blood cancer drug CTL019 has shown positive results in a Phase II trial, positioning the company to come out on top in the race to approval for precision T-cell drugs.
Clinical Researcher of the Year – The Americas: competition closing date approaching
The entry deadline for this unique learning and development opportunity is 28 January 2016, so don’t delay!
Time is running out! Enter International Clinical Researcher of the Year
You’ve only got three weeks left to submit your essay for the International Clinical Researcher of the Year competition for 2016, and with Christmas approaching, time is limited.
UK paying less for cancer drugs than other EU countries
The UK is paying less for new cancer drugs than most other countries in Europe, a new report has found.
